Flotufolastat F18 (POSLUMA®) was FDA-approved in May 2023 for PET imaging of patients with prostate cancer with suspected metastases or high serum prostate-specific antigen levels and suspected recurrence [111]. Here, KLK3 is linked to prostate carcinoma.